A multicentre verification study of the QuantiFERON®-TB Gold Plus assay

E. D. Pieterman, F. G. Liqui Lung, A. Verbon, H. I. Bax, C. W. Ang, J. Berkhout, G. Blaauw, A. Brandenburg, N. D. van Burgel, A. Claessen, K. van Dijk, M. Heron, M. Hooghiemstra, R. Leussenkamp-Hummelink, E. van Lochem, I. H.M. van Loo, B. Mulder, A. Ott, O. Pontesilli, A. Reuwer & 5 others P. Rombouts, V. Saegeman, M. Scholing, S. Vainio, J. E.M. de Steenwinkel

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Objectives The aim of this verification study was to compare the QuantiFERON®-TB Gold Plus (QFT-Plus) to the QuantiFERON®-TB Gold In Tube (QFT-GIT). The new QFT-Plus test contains an extra antigen tube which, according to the manufacturer additionally elicits a CD8+ T-cell response above the CD4+ T-cell response. We assessed the value of this tube in detecting recent latent tuberculosis infections. Methods Between May 2015 and December 2016, 1031 subjects underwent QFT-Plus and QFT-GIT test. Overall agreement between both tests and performance for different test indications and/or immune states was assessed. A difference of >0.6 IU/mL interferon-γ release between the two antigen tubes of the QFT-Plus assay was considered a true difference and used as estimation for CD8+ T-cell response. Results Analysis of the QuantiFERON tests resulted in an overall agreement between assays of 95%. Subjects considered to be recently exposed to tuberculosis had significantly more often a true difference in interferon-γ release compared to all other subjects (p = 0.029). Conclusion Results of QFT-Plus are highly comparable to QFT-GIT. Although there is an indication that a true difference in interferon-γ release between the antigen tubes is associated with recent latent tuberculosis infection, the QFT-Plus could not be used to exclude recent exposure.

Original languageEnglish
Pages (from-to)136-142
Number of pages7
JournalTuberculosis
Volume108
DOIs
Publication statusPublished - 1 Jan 2018

Cite this

Pieterman, E. D., Liqui Lung, F. G., Verbon, A., Bax, H. I., Ang, C. W., Berkhout, J., ... de Steenwinkel, J. E. M. (2018). A multicentre verification study of the QuantiFERON®-TB Gold Plus assay. Tuberculosis, 108, 136-142. https://doi.org/10.1016/j.tube.2017.11.014
Pieterman, E. D. ; Liqui Lung, F. G. ; Verbon, A. ; Bax, H. I. ; Ang, C. W. ; Berkhout, J. ; Blaauw, G. ; Brandenburg, A. ; van Burgel, N. D. ; Claessen, A. ; van Dijk, K. ; Heron, M. ; Hooghiemstra, M. ; Leussenkamp-Hummelink, R. ; van Lochem, E. ; van Loo, I. H.M. ; Mulder, B. ; Ott, A. ; Pontesilli, O. ; Reuwer, A. ; Rombouts, P. ; Saegeman, V. ; Scholing, M. ; Vainio, S. ; de Steenwinkel, J. E.M. / A multicentre verification study of the QuantiFERON®-TB Gold Plus assay. In: Tuberculosis. 2018 ; Vol. 108. pp. 136-142.
@article{901e29ae917c43b5b37438fb2397c302,
title = "A multicentre verification study of the QuantiFERON{\circledR}-TB Gold Plus assay",
abstract = "Objectives The aim of this verification study was to compare the QuantiFERON{\circledR}-TB Gold Plus (QFT-Plus) to the QuantiFERON{\circledR}-TB Gold In Tube (QFT-GIT). The new QFT-Plus test contains an extra antigen tube which, according to the manufacturer additionally elicits a CD8+ T-cell response above the CD4+ T-cell response. We assessed the value of this tube in detecting recent latent tuberculosis infections. Methods Between May 2015 and December 2016, 1031 subjects underwent QFT-Plus and QFT-GIT test. Overall agreement between both tests and performance for different test indications and/or immune states was assessed. A difference of >0.6 IU/mL interferon-γ release between the two antigen tubes of the QFT-Plus assay was considered a true difference and used as estimation for CD8+ T-cell response. Results Analysis of the QuantiFERON tests resulted in an overall agreement between assays of 95{\%}. Subjects considered to be recently exposed to tuberculosis had significantly more often a true difference in interferon-γ release compared to all other subjects (p = 0.029). Conclusion Results of QFT-Plus are highly comparable to QFT-GIT. Although there is an indication that a true difference in interferon-γ release between the antigen tubes is associated with recent latent tuberculosis infection, the QFT-Plus could not be used to exclude recent exposure.",
keywords = "Interferon-gamma release assay, Latent tuberculosis infection, QuantiFERON-TB Gold In Tube, QuantiFERON-TB Gold Plus, Tuberculosis",
author = "Pieterman, {E. D.} and {Liqui Lung}, {F. G.} and A. Verbon and Bax, {H. I.} and Ang, {C. W.} and J. Berkhout and G. Blaauw and A. Brandenburg and {van Burgel}, {N. D.} and A. Claessen and {van Dijk}, K. and M. Heron and M. Hooghiemstra and R. Leussenkamp-Hummelink and {van Lochem}, E. and {van Loo}, {I. H.M.} and B. Mulder and A. Ott and O. Pontesilli and A. Reuwer and P. Rombouts and V. Saegeman and M. Scholing and S. Vainio and {de Steenwinkel}, {J. E.M.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.tube.2017.11.014",
language = "English",
volume = "108",
pages = "136--142",
journal = "Tuberculosis",
issn = "1472-9792",
publisher = "Churchill Livingstone",

}

Pieterman, ED, Liqui Lung, FG, Verbon, A, Bax, HI, Ang, CW, Berkhout, J, Blaauw, G, Brandenburg, A, van Burgel, ND, Claessen, A, van Dijk, K, Heron, M, Hooghiemstra, M, Leussenkamp-Hummelink, R, van Lochem, E, van Loo, IHM, Mulder, B, Ott, A, Pontesilli, O, Reuwer, A, Rombouts, P, Saegeman, V, Scholing, M, Vainio, S & de Steenwinkel, JEM 2018, 'A multicentre verification study of the QuantiFERON®-TB Gold Plus assay' Tuberculosis, vol. 108, pp. 136-142. https://doi.org/10.1016/j.tube.2017.11.014

A multicentre verification study of the QuantiFERON®-TB Gold Plus assay. / Pieterman, E. D.; Liqui Lung, F. G.; Verbon, A.; Bax, H. I.; Ang, C. W.; Berkhout, J.; Blaauw, G.; Brandenburg, A.; van Burgel, N. D.; Claessen, A.; van Dijk, K.; Heron, M.; Hooghiemstra, M.; Leussenkamp-Hummelink, R.; van Lochem, E.; van Loo, I. H.M.; Mulder, B.; Ott, A.; Pontesilli, O.; Reuwer, A.; Rombouts, P.; Saegeman, V.; Scholing, M.; Vainio, S.; de Steenwinkel, J. E.M.

In: Tuberculosis, Vol. 108, 01.01.2018, p. 136-142.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - A multicentre verification study of the QuantiFERON®-TB Gold Plus assay

AU - Pieterman, E. D.

AU - Liqui Lung, F. G.

AU - Verbon, A.

AU - Bax, H. I.

AU - Ang, C. W.

AU - Berkhout, J.

AU - Blaauw, G.

AU - Brandenburg, A.

AU - van Burgel, N. D.

AU - Claessen, A.

AU - van Dijk, K.

AU - Heron, M.

AU - Hooghiemstra, M.

AU - Leussenkamp-Hummelink, R.

AU - van Lochem, E.

AU - van Loo, I. H.M.

AU - Mulder, B.

AU - Ott, A.

AU - Pontesilli, O.

AU - Reuwer, A.

AU - Rombouts, P.

AU - Saegeman, V.

AU - Scholing, M.

AU - Vainio, S.

AU - de Steenwinkel, J. E.M.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objectives The aim of this verification study was to compare the QuantiFERON®-TB Gold Plus (QFT-Plus) to the QuantiFERON®-TB Gold In Tube (QFT-GIT). The new QFT-Plus test contains an extra antigen tube which, according to the manufacturer additionally elicits a CD8+ T-cell response above the CD4+ T-cell response. We assessed the value of this tube in detecting recent latent tuberculosis infections. Methods Between May 2015 and December 2016, 1031 subjects underwent QFT-Plus and QFT-GIT test. Overall agreement between both tests and performance for different test indications and/or immune states was assessed. A difference of >0.6 IU/mL interferon-γ release between the two antigen tubes of the QFT-Plus assay was considered a true difference and used as estimation for CD8+ T-cell response. Results Analysis of the QuantiFERON tests resulted in an overall agreement between assays of 95%. Subjects considered to be recently exposed to tuberculosis had significantly more often a true difference in interferon-γ release compared to all other subjects (p = 0.029). Conclusion Results of QFT-Plus are highly comparable to QFT-GIT. Although there is an indication that a true difference in interferon-γ release between the antigen tubes is associated with recent latent tuberculosis infection, the QFT-Plus could not be used to exclude recent exposure.

AB - Objectives The aim of this verification study was to compare the QuantiFERON®-TB Gold Plus (QFT-Plus) to the QuantiFERON®-TB Gold In Tube (QFT-GIT). The new QFT-Plus test contains an extra antigen tube which, according to the manufacturer additionally elicits a CD8+ T-cell response above the CD4+ T-cell response. We assessed the value of this tube in detecting recent latent tuberculosis infections. Methods Between May 2015 and December 2016, 1031 subjects underwent QFT-Plus and QFT-GIT test. Overall agreement between both tests and performance for different test indications and/or immune states was assessed. A difference of >0.6 IU/mL interferon-γ release between the two antigen tubes of the QFT-Plus assay was considered a true difference and used as estimation for CD8+ T-cell response. Results Analysis of the QuantiFERON tests resulted in an overall agreement between assays of 95%. Subjects considered to be recently exposed to tuberculosis had significantly more often a true difference in interferon-γ release compared to all other subjects (p = 0.029). Conclusion Results of QFT-Plus are highly comparable to QFT-GIT. Although there is an indication that a true difference in interferon-γ release between the antigen tubes is associated with recent latent tuberculosis infection, the QFT-Plus could not be used to exclude recent exposure.

KW - Interferon-gamma release assay

KW - Latent tuberculosis infection

KW - QuantiFERON-TB Gold In Tube

KW - QuantiFERON-TB Gold Plus

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=85036573566&partnerID=8YFLogxK

U2 - 10.1016/j.tube.2017.11.014

DO - 10.1016/j.tube.2017.11.014

M3 - Article

VL - 108

SP - 136

EP - 142

JO - Tuberculosis

JF - Tuberculosis

SN - 1472-9792

ER -

Pieterman ED, Liqui Lung FG, Verbon A, Bax HI, Ang CW, Berkhout J et al. A multicentre verification study of the QuantiFERON®-TB Gold Plus assay. Tuberculosis. 2018 Jan 1;108:136-142. https://doi.org/10.1016/j.tube.2017.11.014